Subcutaneous bortezomib for treatment of TEMPI syndrome

Clinical Lymphoma, Myeloma and Leukemia

Volumn 14, Issue 6, 2014, Pages e221-e223

  Jasim, Sina ^a   Mahmud, Gibran ^b   Bastani, Bahar ^b   Fesler, Mark ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

Author keywords

Monoclonal gammopathy; Neuropathy; Perinephric cysts; Polycythemia; Telangiectasia

Indexed keywords

BORTEZOMIB; ERYTHROPOIETIN; HEMOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN LAMBDA CHAIN; BORONIC ACID DERIVATIVE; PROTEASOME INHIBITOR; PYRAZINE DERIVATIVE;

ADULT; AMYLOIDOSIS; ARTERIAL GAS; ARTICLE; BACKACHE; BODY FLUID; BONE DENSITY; BONE MARROW BIOPSY; CASE REPORT; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; DECORTICATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ECHOGRAPHY; ELEVATED BLOOD PRESSURE; EPIGASTRIC FULLNESS; ERYTHROCYTOSIS; FEMALE; HEMATOCRIT; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOXEMIA; IMMUNOGLOBULIN BLOOD LEVEL; KIDNEY BIOPSY; KIDNEY CYST; LAPAROSCOPIC SURGERY; LIVER HEMANGIOMA; LUMBAR DISK HERNIA; LUMBOSACRAL RADICULOPATHY; LYMPHOCYTIC COLITIS; MIDDLE AGED; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPENIA; PATHOGENESIS; PERINEPHRIC FLUID; PERIPHERAL NEUROPATHY; PLASMA CELL; RADICULOPATHY; SYSTEMIC DISEASE; TELANGIECTASIA; TELANGIECTASIA ERYTHROCYTOSIS WITH ELEVATED ERYTHROPOIETIN LEVELS MONOCLONAL GAMMOPATHY PERINEPHRIC FLUID COLLECTIONS AND INTRAPULMONARY SHUNTING SYNDROME; EDEMA; PARAPROTEINEMIAS; PATHOLOGY; POLYCYTHEMIA; SKIN; TELANGIECTASIS; TREATMENT OUTCOME;

BORONIC ACIDS; EDEMA; FEMALE; HUMANS; MIDDLE AGED; PARAPROTEINEMIAS; POLYCYTHEMIA; PROTEASOME INHIBITORS; PYRAZINES; SKIN; TELANGIECTASIS; TREATMENT OUTCOME;

EID: 84922552208     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2014.07.004     Document Type: Article

References (15)

1. Sykes DB, Schroyens W, O'Connell C. The TEMPI syndrome-A novel multisystem disease. N Engl J Med 2011; 365:475-7
2. Bazari H, Attar EC, Dahl DM, et al. Case records of the Massachusetts General Hospital (case 23-2010: A 49-year-old man with erythrocytosis, perinephric fluid collections, and renal failure.). N Engl J Med 2010; 363:463-75
3. Burton IE, Sambrook P, McWilliam LJ. Secondary polycythaemia associated with bilateral renal lymphocoeles. Postgrad Med J 1994; 70:515-7
4. Olerud JE, Robertson HT, Hossack KF, et al. A patient with polycythemia. West J Med 1981; 135:375-82
5. Shaheen M, Hilgarth KA, Hawes D, et al. A Mexican man with "too much blood." Lancet 2003; 362:806
6. Kwok M, Korde N, Landgren O. Bortezomib to treat the TEMPI syndrome. N Engl J Med 2012; 366:1843-5
7. Mohammadi F, Wolverson M, Bastani B. A new case of TEMPI syndrome. Clin Kidney J 2012; 5:556-8
8. Schroyens W, O'Connell C, Skyes D. Complete and partial responses of the TEMPI syndrome to bortezomib. N Engl J Med 2012; 367:778-80
9. Viglietti D, SverzutJ M, Peraldi MN. Perirenal fluid collections and monoclonal gammopathy. Nephro Dial Transplant 2012; 27:448-9
10. Chen Z, Qi L, Tang Z, et al. Renal lymphangiectasia. Scan J Urol Nephrol 2009; 43:428-30
11. Engelhardt M, Kleber M, Udi J, et al. Consensus statement from European experts on the diagnosis, management and treatment of multiple myeloma: from standard therapy to novel approaches. Leuk Lymphoma 2010; 51:1424-43
12. Antoine JC, Camdessanche JP. Peripheral nervous system involvement in patients with cancer. Lancet Neurol 2007; 6:75-86
13. Moreau P, Coiteux V, Hulin C, et al. Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica 2008; 93:1908-11
14. Lamm W, Drach-Schauer B, Eder S, Drach J. Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma. Oncology 2013; 85:223-7
15. Harvey RD. Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib. Clin Pharmacol 2014; 6:87-96.